Integrated Filing — IndAS



General information about company

Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 03-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 03-11-2026   19:30:00
End date and time of board meeting 04-11-2026   00:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 12-02-2026
Indicate Company website link for updated RPT policy of the Company https://www.lupin.com/uploads/Policy_on_Related_Party_Transactions_6e91aa0e1d.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for the default on Loans and Debt Securities is not applicable to the Company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 3,56,734.00 10,73,924.00
Other income 9,552.00 19,800.00
Total income 3,66,286.00 10,93,724.00
2 Expenses
(a) Cost of materials consumed 1,01,427.00 2,06,482.00
(b) Purchases of stock-in-trade 33,886.00 64,776.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (8,108.00) (9,104.00)
(d) Employee benefit expense 74,698.00 1,46,667.00
(e) Finance costs 3,255.00 6,811.00
(f) Depreciation, depletion and amortisation expense 19,312.00 38,313.00
(f) Other Expenses
1 Other expenses 1,42,308.00 2,78,507.00
2 Net (gain) / loss on foreign currency transactions (8,604.00) (7,846.00)
Total other expenses 1,33,704.00 2,70,661.00
Total expenses 3,58,174.00 7,24,606.00
3 Total profit before exceptional items and tax 8,112.00 3,69,118.00
4 Exceptional items (7,693.00) (7,693.00)
5 Total profit before tax 419.00 3,61,425.00
6 Tax expense
7 Current tax 323.00 89,580.00
8 Deferred tax 687.00 976.00
9 Total tax expenses 1,010.00 90,556.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (591.00) 2,70,869.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (591.00) 2,70,869.00
17 Other comprehensive income net of taxes 53.00 759.00
18 Total Comprehensive Income for the period (538.00) 2,71,628.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 9,146.00 9,146.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.13 59.24
Diluted earnings (loss) per share from continuing operations -0.13 58.94
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.13 59.24
Diluted earnings (loss) per share from continuing and discontinued operations -0.13 58.94
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes accompanying to the standalone financial results. 1. The above Standalone Financial Results were reviewed by the Audit Committee on November 02, 2026 and thereafter approved and taken on record by the Board of Directors at their meeting held on November 03, 2026. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. The Standalone Financial Results are prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. During the quarter ended September 30, 2026, 57,436 (year to date 110,861) equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up equity share capital by Rs. 0.1 million (year to date Rs. 0.2 million) and securities premium account by Rs. 87.1 million (year to date Rs. 164.0 million). 4. As approved by the Members of the Company at the 44th Annual General Meeting held on August 04, 2026, the Company has disbursed on August 06, 2026 a final dividend of Rs. 18/- per equity share of the face value of Rs. 2/- each aggregating Rs. 8,230.2 million. 5. Exceptional items a. During the quarter ended and six months ended September 30, 2026, the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of Rs. 769.3 million. b. The Company and its subsidiary are exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and a possible violation of federal and state antitrust laws.These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the year ended March 31 2026, the Company on best estimate recorded a provision of Rs. 4,493.9 million (USD 50.0 million) towards this litigation without admission of liability or wrongdoing. During the quarter ended March 31, 2026, this provision has been recorded by the subsidiary and consequently reversed in the standalone results. During the period ended September 30, 2026, the wholly owned subsidiary settled one of the ongoing antitrust matters for an amount of Rs. 3,162.8 million (USD 35.8 million) without admission of liability or wrongdoing. c. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets and agreed to pay USD 90.0 million. During the year ended March 31, 2026, the Company has compensated Lupin Pharmaceuticals, Inc., U.S.A., for the settlement payment of Rs. 1,364.7 million (USD 15.0 million) made by it and accordingly expensed. The balance amount of USD 75.0 million towards prepaid option has been paid and capitalised by the subsidiary. d. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the New Labour Codes). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 496.4 million during the year ended March 31, 2026. e. During the previous periods ended September 30, 2025 and March 31, 2026, the Company transferred its Over the Counter ('OTC') and API R&D business in India to its wholly owned subsidiaries Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, as a going concern on slump sale basis for a consideration of Rs. 8,200.0 million and Rs. 180.0 million resulting in gain on divestment of Rs. 6,589.6 million and Rs. 37.2 million respectively. f. During the previous periods ended September 30, 2025 and March 31, 2026, the Company has determined that the carrying value of investment in a wholly owned subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of Rs. 700.0 million.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,68,307.00
Capital work-in-progress 61,213.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 1,04,273.00
Intangible assets under development 9,602.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 14,97,091.00
Trade receivables, non-current 0.00
Loans, non-current 11,843.00
Other non-current financial assets
1 Other Non-Current Financial Assets 46,988.00
Total of other non-current financial assets 46,988.00
Total non-current financial assets 15,55,922.00
Deferred tax assets (net) 0.00
Other non-current assets
1 Non-Current Tax Assets (Net) 3,139.00
2 Other Non-Current Assets 18,565.00
Total of other non-current assets 21,704.00
Total non-current assets 21,21,021.00
2 Current assets
Inventories 3,74,179.00
Current financial asset
Current investments 3,98,815.00
Trade receivables, current 7,13,664.00
Cash and cash equivalents 16,543.00
Bank balance other than cash and cash equivalents 1,586.00
Loans, current 5,317.00
Other current financial assets
Total of other current financial assets 46,880.00
Total current financial assets 11,82,805.00
Current tax assets (net) 0.00
Other current assets
1 Other Current Assets 1,43,342.00
Total of other current assets 1,43,342.00
Total current assets 17,00,326.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 38,21,347.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 9,146.00
Other equity 32,02,742.00
Total equity attributable to owners of parent 32,11,888.00
Non controlling interest
Total equity 32,11,888.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 32,263.00
2 Other Non-Current Financial Liabilities 3,825.00
Total of other non-current financial liabilities 36,088.00
Total non-current financial liabilities 36,088.00
Provisions, non-current 49,606.00
Deferred tax liabilities (net) 13,636.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other Non-Current Liabilities 14,334.00
Total of other non-current liabilities 14,334.00
Total non-current liabilities 1,13,664.00
Current liabilities
Current financial liabilities
Borrowings, current 46,642.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 12,430.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,80,654.00
Total Trade payable 2,93,084.00
Other current financial liabilities
1 Lease Liabilities 15,302.00
2 Other Current Financial Liabilities 41,561.00
Total of other current financial liabilities 56,863.00
Total current financial liabilities 3,96,589.00
Other current liabilities 35,762.00
1 Other Current Liabilities 35,762.00
Total of other current liabilities 35,762.00
Provisions, current 17,956.00
Current tax liabilities (Net) 45,488.00
Deferred government grants, Current 0.00
Total current liabilities 4,95,795.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 6,09,459.00
Total equity and liabilites 38,21,347.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss (434.00) (442.00)
Total Amount of items that will not be reclassified to profit and loss (434.00) (442.00)
2 Income tax relating to items that will not be reclassified to profit or loss (151.00) (154.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 518.00 1,610.00
Total Amount of items that will be reclassified to profit and loss 518.00 1,610.00
4 Income tax relating to items that will be reclassified to profit or loss 182.00 563.00
5 Total Other comprehensive income 53.00 759.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,61,425.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 6,811.00
Adjustments for decrease (increase) in inventories (39,101.00)
Adjustments for decrease (increase) in trade receivables, current (48,912.60)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (40,639.00)
Adjustments for decrease (increase) in other non-current assets (54.00)
Adjustments for other financial assets, non-current (127.20)
Adjustments for other financial assets, current 21,458.80
Adjustments for other bank balances 958.00
Adjustments for increase (decrease) in trade payables, current 42,388.10
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (2,795.00)
Adjustments for increase (decrease) in other non-current liabilities 409.00
Adjustments for depreciation and amortisation expense 38,313.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 7,340.00
Adjustments for provisions, current 175.00
Adjustments for provisions, non-current 2,628.00
Adjustments for other financial liabilities, current (3,442.00)
Adjustments for other financial liabilities, non-current 665.00
Adjustments for unrealised foreign exchange losses gains 25,523.50
Adjustments for dividend income 0.00
Adjustments for interest income 4,745.90
Adjustments for share-based payments 2,917.20
Adjustments for fair value losses (gains) (9,206.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (1,953.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 2.30
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,386.80)
Net cash flows from (used in) operations 3,60,038.20
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 98,361.20
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,61,677.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 71,012.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 334.00
Purchase of property, plant and equipment 46,310.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 4,021.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (38,309.00)
Net cash flows from (used in) investing activities (1,51,276.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 726.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 11,046.00
Payments of lease liabilities 7,395.00
Dividends paid 82,302.00
Interest paid 5,004.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (1,05,021.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 5,380.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 5,380.00
Cash and cash equivalents cash flow statement at beginning of period 11,163.00
Cash and cash equivalents cash flow statement at end of period 16,543.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Advance - 0.00 4,800.00 4,800.00
2 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Advance - 0.00 148.30 148.30
3 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 90.20 0.00 0.00
4 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 54.70 76.90
5 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 193.00 575.10
6 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 60.30 307.50
7 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 253.10 291.00
8 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 13.50 32.90
9 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 9.00 10.60
10 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 480.80 1,517.20
11 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 2,266.60 2,787.70
12 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 3,782.70 4,494.40
13 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 3.70 3.10
14 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 5,710.00 4,547.90
15 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 10,317.60 13,788.10
16 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 12.90 5.30
17 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 571.00 603.80
18 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 23,135.20 5,516.00
19 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 7,781.40 8,875.30
20 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 2.10 2.10
21 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Creditors - 0.00 85.30 0.00
22 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Creditors - 0.00 84.00 1,105.60
23 Lupin Limited S. N. Pharma Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors - 0.00 0.20 0.00
24 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Creditors - 0.00 43.10 0.00
25 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 4,617.70 6,937.60
26 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 6,774.90 3,438.80
27 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 5,772.30 4,454.10
28 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 22,044.20 20,752.20
29 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 82,620.90 38,732.80
30 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 52.10 40.70
31 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 118.60 136.90
32 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 (226.90) 42.20
33 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 4,573.90 7,590.30
34 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 4,39,526.40 4,96,338.50
35 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 7,480.10 5,224.30
36 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 51.60 157.10
37 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 16.20 1.60
38 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Debtors - 0.00 6,781.00 2,463.90
39 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Inter-corporate deposit - 0.00 74.00 74.00
40 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Deposits received balance Premises - 0.00 30.00 30.00
41 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Deposits received balance Premises - 0.00 1.00 0.00
42 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements 100.00 Approved 1.00 0.00 0.00
43 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 25.20 74.70
44 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 39.00 163.10
45 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 62.10 405.20
46 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 116.30 342.40
47 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 138.10 3.80
48 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 61.10 3.20
49 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 33.20 196.30
50 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 50.60 2,699.60
51 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 0.60 10.30
52 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 493.70 1,959.30
53 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 117.80 343.50
54 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 0.00 5.10
55 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 16.30 90.20
56 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 140.90 864.30
57 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 133.80 175.20
58 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 2.50 10.50
59 Lupin Limited Medisol S.A.S., France Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 0.00 67.90
60 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 27.80 33.70
61 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Expenses receivable - 0.00 21.70 49.10
62 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 126.40 113.80
63 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 56.90 123.00
64 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Expenses receivable - 0.00 22.50 90.20
65 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expenses receivable - 0.00 0.10 0.00
66 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses Payable - 0.00 279.90 548.30
67 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 25.70 0.00 0.00
68 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 207.30 0.00 0.00
69 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 18.80 0.00 0.00
70 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 549.70 0.00 0.00
71 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 1,491.20 0.00 0.00
72 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 532.30 0.00 0.00
73 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 63.30 0.00 0.00
74 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 22.20 0.00 0.00
75 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 307.90 0.00 0.00
76 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 4,349.10 0.00 0.00
77 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses Reimbursed - 1.60 0.00 0.00
78 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expenses Reimbursed 100.00 Approved 8.60 0.00 0.00
79 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 1,000.00 Approved 307.80 0.00 0.00
80 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 300.00 Approved 93.00 0.00 0.00
81 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Guarantee Fees Income 700.00 Approved 234.10 0.00 0.00
82 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 42.90 46.50
83 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 13.70 14.40
84 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 539.50 818.60
85 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 1.50 1.20
86 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 61.70 140.90
87 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 9.20 15.30
88 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 2.50 2.50
89 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 12.00 13.10
90 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 1,472.20 456.50
91 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 650.30 454.60
92 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 10.90 12.10
93 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 2,531.70 524.10
94 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 1.40 0.80
95 Lupin Limited Lupin Oncology Inc., USA Subsidiary Any other transaction Income Receivable - 0.00 2,525.00 3,838.30
96 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 26.50 35.40
97 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 321.90 250.30
98 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 5.00 2.30
99 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 22.40 22.60
100 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 10.20 186.30
101 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 45.00 46.90
102 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Income Receivable - 0.00 16.80 13.70
103 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 493.30 916.20
104 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 20.00 19.80
105 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 23.30 27.70
106 Lupin Limited Southern Cross Pharma Pty Ltd., Australia Wholly -Owned Subsidiary Any other transaction Income Receivable - 0.00 3.00 2.10
107 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Interest received - 88.80 0.00 0.00
108 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Interest received - 0.10 0.00 0.00
109 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Interest received - 467.00 0.00 0.00
110 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Interest received - 164.60 0.00 0.00
111 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Investment - 2,490.00 0.00 0.00
112 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Investment - 28,438.50 0.00 0.00
113 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Investment - 2,53,800.20 0.00 0.00
114 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Investment - 0.00 3,28,055.60 3,28,055.60
115 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Investment - 0.00 333.20 333.20
116 Lupin Limited Lupin Biologics Limited, India Wholly -Owned Subsidiary Investment - 0.00 15.00 15.00
117 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Investment - 0.00 43,816.60 43,816.60
118 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Investment - 0.00 25,000.00 27,490.00
119 Lupin Limited Lupin Lanka (Private) Ltd., Sri Lanka Wholly -Owned Subsidiary Investment - 0.00 167.50 167.50
120 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Investment - 0.00 2,510.00 2,510.00
121 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Investment - 0.00 1,14,450.00 1,42,888.50
122 Lupin Limited Lupin Oncology Inc., USA Subsidiary Investment - 0.00 11,278.50 11,278.50
123 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Investment - 0.00 137.90 137.90
124 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Investment - 0.00 90,010.00 90,010.00
125 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Investment - 0.00 6,12,654.50 8,66,454.80
126 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Loan - 0.00 0.00 5,000.00 Loan 7.0500 1 year Unsecured Business Purpose
127 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Loan - 0.00 12,500.00 11,500.00 Loan 8.00 5 years Unsecured Business Purpose
128 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Loan - 0.00 10,000.00 0.00 Loan 7.0500 1 year Unsecured Business Purpose
129 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Loan - 5,000.00 0.00 0.00 Loan 7.0500 1 year Unsecured Business Purpose
130 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Loan - 150.00 0.00 0.00 Loan 7.0500 3 months Unsecured Business Purpose
131 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Loan - 150.00 0.00 0.00 Loan 7.0500 3 months Unsecured Business Purpose Textual Information(1)
132 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Loan - 1,000.00 0.00 0.00 Loan 8.00 5 years Unsecured Business Purpose Textual Information(2)
133 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Loan - 10,000.00 0.00 0.00 Loan 7.0500 1 year Unsecured Business Purpose Textual Information(3)
134 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Product Development Expense 9,500.00 Approved 7,624.20 0.00 0.00
135 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Product Development Expense 840.00 Approved 753.00 0.00 0.00
136 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 3,000.00 Approved 635.00 0.00 0.00
137 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Purchase of goods or services 63,400.00 Approved 19,840.10 0.00 0.00
138 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 2,100.00 Approved 844.40 0.00 0.00
139 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 110.20 0.00 0.00
140 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 248.90 0.00 0.00
141 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 440.50 0.00 0.00
142 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 434.00 0.00 0.00
143 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 59.00 0.00 0.00
144 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 33.90 0.00 0.00
145 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 232.70 0.00 0.00
146 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 2,699.20 0.00 0.00
147 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 51.90 0.00 0.00
148 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 2,844.00 0.00 0.00
149 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 364.90 0.00 0.00
150 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 6.10 0.00 0.00
151 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 105.50 0.00 0.00
152 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 1,357.30 0.00 0.00
153 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 0.10 0.00 0.00
154 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 187.10 0.00 0.00
155 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 18.70 0.00 0.00
156 Lupin Limited Medisol S.A.S., France Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 68.80 0.00 0.00
157 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 62.20 0.00 0.00
158 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Any other transaction Expenses incurred on their behalf recovered 200.00 Approved 66.60 0.00 0.00
159 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 105.90 0.00 0.00
160 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 161.60 0.00 0.00
161 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Any other transaction Expenses incurred on their behalf recovered - 103.10 0.00 0.00
162 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Expenses incurred on their behalf recovered 100.00 Approved 0.70 0.00 0.00
163 Lupin Limited Mr. Nilesh D. Gupta Key Management Personnel Remuneration 2,000.00 Approved 1,552.70 0.00 0.00
164 Lupin Limited Mrs. Manju D. Gupta Non- Executive Directors Remuneration 90.00 Approved 29.00 0.00 0.00
165 Lupin Limited Ms.Vinita Gupta Key Management Personnel Remuneration 3,610.00 Approved 2,566.60 0.00 0.00
166 Lupin Limited Zyma Properties Pvt. Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Rent expense 200.00 Approved 62.20 0.00 0.00
167 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Any other transaction Rent Income 100.00 Approved 11.50 0.00 0.00
168 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Rent Income 1,520.00 Approved 706.60 0.00 0.00
169 Lupin Limited Polynova Industries Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Any other transaction Rent Income 30.00 Approved 8.10 0.00 0.00
170 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Sale of goods or services 40.00 Approved 25.60 0.00 0.00
171 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Sale of goods or services 100.00 Approved 11.80 0.00 0.00
172 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 2,300.00 Approved 1,091.20 0.00 0.00
173 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 5,400.00 Approved 746.90 0.00 0.00
174 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 3,300.00 Approved 221.80 0.00 0.00
175 Lupin Limited Lupin Oncology Inc., USA Subsidiary Sale of goods or services 5,200.00 Approved 1,280.30 0.00 0.00
176 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 100.00 Approved 5.70 0.00 0.00
177 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Sale of goods or services 800.00 Approved 172.40 0.00 0.00
178 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 20,600.00 Approved 8,264.00 0.00 0.00
179 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 13,800.00 Approved 5,190.50 0.00 0.00
180 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 21,800.00 Approved 5,199.90 0.00 0.00
181 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Sale of goods or services 100.00 Approved 0.50 0.00 0.00
182 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Sale of goods or services 45,400.00 Approved 20,847.10 0.00 0.00
183 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 2,36,800.00 Approved 62,108.10 0.00 0.00
184 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Sale of goods or services 220.00 Approved 59.40 0.00 0.00
185 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 1,600.00 Approved 89.70 0.00 0.00
186 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Sale of goods or services 1,100.00 Approved 128.40 0.00 0.00
187 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Sale of goods or services 25,700.00 Approved 7,692.80 0.00 0.00
188 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 8,99,500.00 Approved 3,36,043.70 0.00 0.00
189 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Sale of goods or services 2,400.00 Approved 1,570.60 0.00 0.00
190 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 400.00 Approved 189.80 0.00 0.00
191 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Sale of goods or services 600.00 Approved 181.70 0.00 0.00
192 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Sale of goods or services 20,900.00 Approved 7,103.50 0.00 0.00
193 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Purchase of goods or services 1,050.00 Approved 404.60 0.00 0.00
194 Lupin Limited Laboratorios Grin, S.A. de C.V., Mexico Wholly -Owned Subsidiary Purchase of goods or services 400.00 Approved 319.70 0.00 0.00
195 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Purchase of goods or services 750.00 Approved 270.90 0.00 0.00
196 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Purchase of goods or services 240.00 Approved 90.10 0.00 0.00
197 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Purchase of goods or services 20.00 Approved 7.40 0.00 0.00
198 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Purchase of goods or services 3,400.00 Approved 1,023.70 0.00 0.00
199 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 2,900.00 Approved 752.20 0.00 0.00
200 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Purchase of goods or services 10.00 Approved 1.60 0.00 0.00
201 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 10,800.00 Approved 4,946.90 0.00 0.00
202 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Purchase of goods or services 100.00 Approved 27.80 0.00 0.00
203 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Purchase of goods or services 700.00 Approved 370.10 0.00 0.00
204 Lupin Limited Shubanprint Pack Pvt. Ltd. Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 500.00 Approved 169.20 0.00 0.00
205 Lupin Limited TeamLease Services Limited Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence) Purchase of goods or services 1,400.00 Approved 430.40 0.00 0.00
206 Lupin Limited Generic Health Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 300.00 Approved 85.00 0.00 0.00
207 Lupin Limited Hormosan Pharma GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 100.00 Approved 30.00 0.00 0.00
208 Lupin Limited Lupin Atlantis Holdings SA, Switzerland Wholly -Owned Subsidiary Sale of goods or services 70.00 Approved 19.70 0.00 0.00
209 Lupin Limited Lupin Australia Pty Limited, Australia Wholly -Owned Subsidiary Sale of goods or services 10.00 Approved 2.60 0.00 0.00
210 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Sale of goods or services 270.00 Approved 126.40 0.00 0.00
211 Lupin Limited Lupin Digital Health Limited, India Wholly -Owned Subsidiary Sale of goods or services 30.00 Approved 6.30 0.00 0.00
212 Lupin Limited Lupin Europe GmbH, Germany Wholly -Owned Subsidiary Sale of goods or services 20.00 Approved 5.40 0.00 0.00
213 Lupin Limited Lupin Healthcare (UK) Limited, UK Wholly -Owned Subsidiary Sale of goods or services 100.00 Approved 25.80 0.00 0.00
214 Lupin Limited Lupin Inc., USA Wholly -Owned Subsidiary Sale of goods or services 100.00 Approved 38.60 0.00 0.00
215 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Sale of goods or services 1,270.00 Approved 253.50 0.00 0.00
216 Lupin Limited Lupin Management, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 60.00 Approved 23.60 0.00 0.00
217 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Sale of goods or services 3,050.00 Approved 1,237.50 0.00 0.00
218 Lupin Limited Lupin NZ Ltd., New Zealand Wholly -Owned Subsidiary Sale of goods or services 10.00 Approved 1.60 0.00 0.00
219 Lupin Limited Lupin Oncology Inc., USA Subsidiary Sale of goods or services 10.00 Approved 0.70 0.00 0.00
220 Lupin Limited Lupin Pharma Canada Limited, Canada Wholly -Owned Subsidiary Sale of goods or services 200.00 Approved 60.70 0.00 0.00
221 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 900.00 Approved 298.80 0.00 0.00
222 Lupin Limited Lupin Philippines, Inc., Philippines Wholly -Owned Subsidiary Sale of goods or services 40.00 Approved 9.20 0.00 0.00
223 Lupin Limited Lupin Research Inc., USA Wholly -Owned Subsidiary Sale of goods or services 150.00 Approved 43.00 0.00 0.00
224 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Sale of goods or services 1,100.00 Approved 286.50 0.00 0.00
225 Lupin Limited Multicare Pharmaceuticals Philippines, Inc., Philippines Subsidiary Sale of goods or services 100.00 Approved 28.80 0.00 0.00
226 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Sale of goods or services 50.00 Approved 16.20 0.00 0.00
227 Lupin Limited Novel Laboratories, Inc., USA Wholly -Owned Subsidiary Sale of goods or services 200.00 Approved 42.00 0.00 0.00
228 Lupin Limited Pharma Dynamics (Proprietary) Limited, South Africa Wholly -Owned Subsidiary Sale of goods or services 200.00 Approved 52.80 0.00 0.00
229 Lupin Limited Southern Cross Pharma Pty Ltd., Australia Wholly -Owned Subsidiary Sale of goods or services 20.00 Approved 5.10 0.00 0.00
230 Lupin Limited Lupin Diagnostics Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company - 0.00 5,000.00 5,000.00
231 Lupin Limited Lupin Life Sciences Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company - 0.00 500.00 500.00
232 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company - 0.00 15,000.00 15,000.00
233 Lupin Limited Lupin Pharmaceuticals, Inc., USA Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company - 0.00 2,86,804.00 2,86,804.00
234 Lupin Limited LUPINLIFE Consumer Healthcare Limited, India Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company - 0.00 5,000.00 5,000.00
235 Lupin Limited Medquimica Industria Farmaceutica LTDA, Brazil Wholly -Owned Subsidiary Any other transaction Corporate guarantees issued by the Company to the bankers of subsidiary company - 0.00 42,122.00 42,122.00
236 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Guarantees issued by the Company on behalf of subsidiary companies for contractual obligations - 0.00 63,486.00 63,486.00
237 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Rent Income - 2.80 0.00 0.00
238 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 500.00 Approved 130.30 0.00 0.00
239 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Purchase of goods or services 2,600.00 Approved 1,465.70 0.00 0.00
240 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Payables - 0.00 7,777.40 866.70
241 Multicare Pharmaceuticals Philippines, Inc., Philippines Lupin Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Receivables - 0.00 0.70 0.60
242 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Investment - 0.00 16,659.50 16,659.50
243 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Purchase of goods or services - 2.20 0.00 0.00
244 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Purchase of goods or services - 1,403.60 0.00 0.00
245 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Sale of goods or services - 334.30 0.00 0.00
246 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Interest received - 21.00 0.00 0.00
247 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Sale of goods or services - 1.70 0.00 0.00
248 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Loan - 0.00 650.40 668.40 Loan 6.2500 3 years Unsecured Business purpose
249 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Investment - 0.00 253.00 253.00
250 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 31.50 0.00 0.00
251 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivable - 0.00 380.80 691.70
252 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Payable - 0.00 1,616.80 2,314.20
253 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Any other transaction Trade Receivable - 0.00 13.10 332.20
254 Generic Health Pty Limited, Australia Southern Cross Pharma Pty Ltd., Australia Fellow Subsidiary Any other transaction Trade Payable - 0.00 49.40 494.70
255 Generic Health Pty Limited, Australia Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Payable - 0.00 2.20 32.00
256 Generic Health Pty Limited, Australia Lupin NZ Ltd., New Zealand Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 1.20 0.00 0.00
257 Lupin Australia Pty Limited, Australia Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivable - 0.00 16.70 0.00
258 Lupin Manufacturing Solutions Limited, India Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services - 3,978.00 0.00 0.00
259 Lupin Manufacturing Solutions Limited, India Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Receivables - 0.00 1,850.70 5,084.20
260 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Trade Payables - 0.00 729.70 326.20
261 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Purchase of goods or services - 170.50 0.00 0.00
262 Lupin Manufacturing Solutions Limited, India Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 7.30 0.00 0.00
263 Lupin Healthcare (UK) Limited, UK Renascience Pharma Limited, UK Fellow Subsidiary Sale of goods or services - 241.80 0.00 0.00
264 Lupin Healthcare (UK) Limited, UK Renascience Pharma Limited, UK Fellow Subsidiary Any other transaction Trade Receivables - 0.00 611.90 241.50
265 Lupin Pharma Canada Limited, Canada Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Sale of goods or services - 0.70 0.00 0.00
266 Lupin Pharma Canada Limited, Canada Lupin NZ Ltd., New Zealand Fellow Subsidiary Sale of goods or services - 7.60 0.00 0.00
267 Lupin Pharma Canada Limited, Canada Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.20 0.50
268 Lupin Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Sale of goods or services - 148.70 0.00 0.00
269 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Purchase of goods or services - 52.70 0.00 0.00
270 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services - 266.20 0.00 0.00
271 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 804.20 0.00 0.00
272 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Purchase of goods or services - 39.70 0.00 0.00
273 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Sale of goods or services 100.00 Approved 9.70 0.00 0.00
274 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered 100.00 Approved 11.90 0.00 0.00
275 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services - 623.40 0.00 0.00
276 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services - 62.80 0.00 0.00
277 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Purchase of goods or services - 162.20 0.00 0.00
278 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 3.90 0.00 0.00
279 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services - 1,18,607.30 0.00 0.00
280 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services - 587.30 0.00 0.00
281 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 657.30 0.00 0.00
282 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services - 53.10 0.00 0.00
283 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 1,101.90 0.00 0.00
284 Lupin Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 573.70 0.00 0.00
285 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services - 89.10 0.00 0.00
286 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 82.80 0.00 0.00
287 Medisol S.A.S., France Lupin Inc., USA Fellow Subsidiary Sale of goods or services - 8.40 0.00 0.00
288 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Interest received - 23.40 0.00 0.00
289 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 43,696.10 44,801.60
290 Lupin Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Investment - 0.00 98,324.10 1,05,760.40
291 Lupin Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables - 0.00 2,302.70 579.40
292 Lupin Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Payables - 0.00 3.20 0.00
293 Lupin Inc., USA Medisol S.A.S., France Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.00 8.40
294 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 19,559.10 17,934.10
295 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Loan - 0.00 0.00 11,499.40 Loan 0 1 year Unsecured Business purpose
296 Lupin Inc., USA Lupin Research Inc., USA Fellow Subsidiary Investment - 0.00 26,705.00 28,604.30
297 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 1,52,313.80 1,82,534.30
298 Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Investment - 0.00 62,364.00 77,973.20
299 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Payables - 0.00 7.90 0.00
300 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables - 0.00 209.20 665.40
301 Lupin Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.00 163.50
302 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 15.70 21.70
303 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Investment - 0.00 38,971.60 39,489.00
304 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Loan - 0.00 0.00 958.30 Loan 4.900 2.5 years Unsecured Business purpose
305 Lupin Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Loan - 0.00 0.00 47.60
306 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables - 0.00 35.60 0.00
307 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables - 0.00 45.70 0.00
308 Lupin Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.00 26.70
309 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 626.00 0.00
310 Lupin Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 0.00 818.40
311 Lupin Inc., USA Lupin Australia Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Payables - 0.00 2.40 0.00
312 Lupin Management, Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Sale of goods or services - 59.70 0.00 0.00
313 Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Sale of goods or services - 153.30 0.00 0.00
314 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services - 4,107.90 0.00 0.00
315 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 2.00 0.00 0.00
316 Lupin Management, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 1.60 0.00 0.00
317 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Sale of goods or services - 415.90 0.00 0.00
318 Lupin Management, Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Sale of goods or services 200.00 Approved 61.00 0.00 0.00
319 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services - 117.70 0.00 0.00
320 Lupin Management, Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services - 716.20 0.00 0.00
321 Lupin Management, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services - 210.30 0.00 0.00
322 Lupin Management, Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services - 145.50 0.00 0.00
323 Lupin Management, Inc., USA Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Sale of goods or services 200.00 Approved 88.00 0.00 0.00
324 Nanomi B.V., Netherlands Lupin Management, Inc., USA Fellow Subsidiary Purchase of goods or services - 804.50 0.00 0.00
325 Lupin Management, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services - 118.90 0.00 0.00
326 Lupin Management, Inc., USA Lupin Nz Ltd., New Zealand Fellow Subsidiary Sale of goods or services - 11.90 0.00 0.00
327 Lupin Management, Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivables - 0.00 1.80 42.20
328 Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Receivables - 0.00 93.60 75.90
329 Lupin Management, Inc., USA Lupin Oncology Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 48.20 61.50
330 Lupin Management, Inc., USA Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Trade Receivables - 0.00 370.90 521.60
331 Lupin Management, Inc., USA Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Any other transaction Trade Receivables - 0.00 104.60 41.50
332 Lupin Management, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables - 0.00 1,190.80 2,014.40
333 Lupin Management, Inc., USA Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Trade Receivables - 0.00 26.70 27.00
334 Lupin Management, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables - 0.00 1,239.50 419.00
335 Lupin Management, Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Receivables - 0.00 44.80 75.30
336 Lupin Management, Inc., USA Lupin Nz Ltd., New Zealand Fellow Subsidiary Any other transaction Trade Receivables - 0.00 16.80 8.40
337 Lupin Oncology Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services 7,500.00 Approved 1,521.30 0.00 0.00
338 Lupin Pharmaceuticals, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 1,824.10 0.00 0.00
339 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 531.80 0.00 0.00
340 Lupin Pharmaceuticals, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 107.80 0.00 0.00
341 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services - 36.90 0.00 0.00
342 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 467.20 0.00 0.00
343 Nanomi B.V., Netherlands Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Sale of goods or services - 3,204.80 0.00 0.00
344 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Sale of goods or services - 26.70 0.00 0.00
345 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 209.10 0.00 0.00
346 Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 296.60 370.70
347 Lupin Pharmaceuticals, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Receivables - 0.00 261.80 226.00
348 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 754.20 228.00
349 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 55.50 0.00
350 Lupin Pharmaceuticals, Inc., USA Novel Laboratories, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 21.90 145.70
351 Lupin Pharmaceuticals, Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Payables - 0.00 454.00 2,180.20
352 Lupin Research Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services - 27,982.60 0.00 0.00
353 Lupin Research Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 141.60 0.00 0.00
354 Lupin Research Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 0.20 0.00 0.00
355 Lupin Research Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Purchase of goods or services - 221.50 0.00 0.00
356 Lupin Research Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 60.00 0.00 0.00
357 Nanomi B.V., Netherlands Lupin Research Inc., USA Fellow Subsidiary Sale of goods or services - 177.00 0.00 0.00
358 Lupin Research Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 0.30 0.00 0.00
359 Lupin Research Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 45.80 211.70
360 Lupin Research Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Receivables - 0.00 0.00 0.30
361 Lupin Research Inc., USA Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.00 178.30
362 Lupin Research Inc., USA Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.00 223.20
363 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services - 3,377.90 0.00 0.00
364 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Sale of goods or services - 31,061.00 0.00 0.00
365 Novel Laboratories, Inc., USA Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 6.80 0.00 0.00
366 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Purchase of goods or services - 280.50 0.00 0.00
367 Novel Laboratories, Inc., USA Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 459.00 0.00 0.00
368 Novel Laboratories, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 28.90 0.00 0.00
369 Novel Laboratories, Inc., USA Lupin Research Inc., USA Fellow Subsidiary Any other transaction Trade Receivables - 0.00 2.90 26.80
370 Novel Laboratories, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Trade Payables - 0.00 118.60 0.00
371 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables - 0.00 3.90 0.00
372 Novel Laboratories, Inc., USA Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Trade Payables - 0.00 0.00 280.70
373 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Loan - 0.00 545.00 1,088.50 Loan 0.7500 2 yrs Unsecured Business Purpose
374 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Loan - 1,089.00 0.00 0.00 Loan 0.7500 2 yrs Unsecured Business Purpose
375 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Receivables - 0.00 31.00 66.80
376 Hormosan Pharma GmbH, Germany Medisol S.A.S., France Fellow Subsidiary Any other transaction Receivables - 0.00 27.80 3.50
377 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Payables - 0.00 114.90 166.20
378 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Interest received - 14.30 0.00 0.00
379 Hormosan Pharma GmbH, Germany Lupin Europe GmbH, Germany Fellow Subsidiary Sale of goods or services - 103.30 0.00 0.00
380 Hormosan Pharma GmbH, Germany Medisol S.A.S., France Fellow Subsidiary Sale of goods or services - 5.50 0.00 0.00
381 Nanomi B.V., Netherlands Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Payables - 0.00 0.00 173.70
382 Nanomi B.V., Netherlands Medisol S.A.S., France Fellow Subsidiary Any other transaction Payables - 0.00 0.00 813.80
383 Nanomi B.V., Netherlands Medisol S.A.S., France Fellow Subsidiary Purchase of goods or services - 359.00 0.00 0.00
384 Nanomi B.V., Netherlands Generic Health Pty Limited, Australia Fellow Subsidiary Investment - 0.00 11,886.70 11,886.70
385 Nanomi B.V., Netherlands Generic Health SDN. BHD., Malaysia Fellow Subsidiary Investment - 0.00 15.10 15.10
386 Nanomi B.V., Netherlands Hormosan Pharma GmbH, Germany Fellow Subsidiary Investment - 0.00 3,107.40 3,107.40
387 Nanomi B.V., Netherlands Lupin Inc., USA Fellow Subsidiary Investment - 0.00 6,72,687.60 6,72,687.60
388 Nanomi B.V., Netherlands Lupin Mexico S.A. de C.V., Mexico Fellow Subsidiary Investment - 0.00 64.50 64.50
389 Nanomi B.V., Netherlands Lupin Philippines, Inc., Philippines Fellow Subsidiary Investment - 0.00 598.90 598.90
390 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Investment - 0.00 4,683.70 4,683.70
391 Nanomi B.V., Netherlands Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Investment - 0.00 2,505.60 39,534.00
392 Nanomi B.V., Netherlands Multicare Pharmaceuticals Philippines, Inc., Philippines Fellow Subsidiary Investment - 37,028.40 0.00 0.00
393 Nanomi B.V., Netherlands Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Investment - 0.00 68,787.80 68,787.80
394 Nanomi B.V., Netherlands VISUfarma B.V., Netherlands Fellow Subsidiary Investment - 2,37,914.50 0.00 0.00
395 Nanomi B.V., Netherlands VISUfarma B.V., Netherlands Fellow Subsidiary Investment - 0.00 0.00 2,37,914.50
396 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan - 0.00 7,190.10 7,666.20 Loan 4.00 3 yrs Unsecured Business Purpose
397 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Interest received - 212.70 0.00 0.00
398 Nanomi B.V., Netherlands Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Purchase of goods or services - 54.60 0.00 0.00
399 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Receivables - 0.00 1,958.60 1,013.40
400 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Receivables - 0.00 335.20 40.00
401 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Receivables - 0.00 2,555.50 1,557.90
402 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Receivables - 0.00 146.10 282.50
403 Lupin Atlantis Holdings SA, Switzerland Lupin Manufacturing Solutions Limited, India Fellow Subsidiary Any other transaction Receivables - 0.00 143.80 406.40
404 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Receivables - 0.00 18,709.60 14,318.80
405 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Any other transaction Receivables - 0.00 762.00 820.10
406 Lupin Atlantis Holdings SA, Switzerland Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Any other transaction Receivables - 0.00 2.20 24.00
407 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Receivables - 0.00 0.00 67.10
408 Lupin Atlantis Holdings SA, Switzerland YL Biologics Ltd., Japan Jointly Controlled Entity Any other transaction Receivables - 0.00 28.50 24.50
409 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Payables - 0.00 43.90 77.00
410 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Payables - 0.00 23.20 69.60
411 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Payables - 0.00 279.30 44.30
412 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Payables - 0.00 117.30 102.60
413 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Payables - 0.00 184.50 143.80
414 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Payables - 0.00 90.80 201.50
415 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Any other transaction Payables - 0.00 246.30 259.50
416 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Payables - 0.00 492.70 630.00
417 Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA Fellow Subsidiary Any other transaction Payables - 0.00 389.40 375.10
418 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Loan - 3,809.90 0.00 0.00 Loan 5.00 9 yrs Unsecured Business Purpose
419 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Loan - 7,608.20 0.00 0.00 Loan 4.2500 9 yrs Unsecured Business Purpose
420 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Investment - 0.00 61,495.50 61,495.50
421 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Investment - 0.00 1,726.20 1,726.20
422 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Investment - 0.00 2,797.50 2,797.50
423 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Investment - 0.00 2,507.60 2,507.60
424 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Investment - 0.00 18,327.70 18,327.70
425 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Investment - 0.00 41,702.50 41,702.50
426 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Interest received - 139.00 0.00 0.00
427 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Interest received - 556.10 0.00 0.00
428 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Interest received - 772.20 0.00 0.00
429 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Interest received - 459.20 0.00 0.00
430 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Interest received - 632.00 0.00 0.00
431 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Sale of goods or services - 1,504.50 0.00 0.00
432 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Sale of goods or services - 6,470.70 0.00 0.00
433 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Sale of goods or services - 1,450.10 0.00 0.00
434 Lupin Atlantis Holdings SA, Switzerland Hormosan Pharma GmbH, Germany Fellow Subsidiary Sale of goods or services - 252.50 0.00 0.00
435 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Sale of goods or services - 29.90 0.00 0.00
436 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Sale of goods or services - 278.10 0.00 0.00
437 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Sale of goods or services - 280.30 0.00 0.00
438 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Sale of goods or services - 179.80 0.00 0.00
439 Lupin Atlantis Holdings SA, Switzerland Pharma Dynamics (Proprietary) Limited, South Africa Fellow Subsidiary Sale of goods or services - 47.60 0.00 0.00
440 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Purchase of goods or services - 99.70 0.00 0.00
441 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Purchase of goods or services - 292.20 0.00 0.00
442 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Purchase of goods or services - 90.60 0.00 0.00
443 Lupin Atlantis Holdings SA, Switzerland Lupin Management, Inc., USA Fellow Subsidiary Purchase of goods or services - 520.60 0.00 0.00
444 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Purchase of goods or services - 1,148.20 0.00 0.00
445 Lupin Atlantis Holdings SA, Switzerland Lupin Research Inc., USA Fellow Subsidiary Purchase of goods or services - 626.50 0.00 0.00
446 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Purchase of goods or services - 0.80 0.00 0.00
447 Lupin Atlantis Holdings SA, Switzerland YL Biologics Ltd., Japan Jointly Controlled Entity Purchase of goods or services - 6.30 0.00 0.00
448 Lupin Atlantis Holdings SA, Switzerland Medisol S.A.S., France Fellow Subsidiary Dividend received - 6,636.10 0.00 0.00
449 Lupin Atlantis Holdings SA, Switzerland Lupin Inc., USA Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 553.10 0.00 0.00
450 Lupin Atlantis Holdings SA, Switzerland Lupin Europe GmbH, Germany Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 152.40 0.00 0.00
451 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 1.80 0.00 0.00
452 Lupin Atlantis Holdings SA, Switzerland Lupin Pharma Canada Limited, Canada Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 5.70 0.00 0.00
453 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Any other transaction Expenses incurred on our behalf reimbursed & Other Reimbursements - 280.00 0.00 0.00
454 Lupin Life Sciences Limited, India LUPINLIFE Consumer Healthcare Limited, India Fellow Subsidiary Any other transaction Expenses incurred on their behalf recovered - 0.00 0.20 0.00
455 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Loan - 0.00 3,485.30 7,355.80 Loan 5.00 9 yrs Unsecured Business Purpose
456 Lupin Atlantis Holdings SA, Switzerland Nanomi B.V., Netherlands Fellow Subsidiary Loan - 0.00 20,858.40 28,748.40 Loan 3.7500 3 yrs Unsecured Business Purpose
457 Lupin Atlantis Holdings SA, Switzerland Lupin Healthcare (UK) Limited, UK Fellow Subsidiary Loan - 0.00 27,534.50 27,996.30 Loan 5.500 2 yrs Unsecured Business Purpose
458 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Loan - 0.00 24,650.90 24,915.30 Loan 4.500 3 yrs Unsecured Business Purpose
459 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Loan - 0.00 18,962.20 19,165.60 Loan 4.7500 3 yrs Unsecured Business Purpose
460 VISUfarma B.V., Netherlands Iris Bidco SRL Italy Fellow Subsidiary Interest received - 632.40 0.00 0.00
461 VISUfarma B.V., Netherlands VISUfarma S.p.A. Italy, Italy Fellow Subsidiary Sale of goods or services - 323.00 0.00 0.00
462 VISUfarma B.V., Netherlands VISUfarma S.p.A. Italy, Italy Fellow Subsidiary Sale of goods or services - 133.90 0.00 0.00
463 VISUfarma B.V., Netherlands VISUfarma UK Limited, UK Fellow Subsidiary Sale of goods or services - 30.90 0.00 0.00
464 VISUfarma S.p.A. Italy, Italy VISUfarma B.V., Netherlands Fellow Subsidiary Sale of goods or services - 2,313.60 0.00 0.00
465 Laboratorios Grin, S.A. de C.V., Mexico Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Sale of goods or services - 56.60 0.00 0.00
466 Lupin Limited Lupin Manufacturing Solutions Limited, India Wholly -Owned Subsidiary Any other transaction Product Development Expense 8,200.00 Approved 3,194.70 0.00 0.00
467 VISUfarma B.V., Netherlands VISUfarma S.p.A. Italy, Italy Fellow Subsidiary Loan - 0.00 0.00 0.00
468 VISUfarma B.V., Netherlands Iris Bidco SAS,France Fellow Subsidiary Loan - 0.00 0.00 0.00
469 Nanomi B.V., Netherlands Hormosan Pharma GmbH, Germany Fellow Subsidiary Any other transaction Capital Contributions - 0.00 0.00 5,497.90
470 Laboratorios Grin, S.A. de C.V., Mexico Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Debtors - 3,194.70 0.00 38.40
471 VISUfarma B.V., Netherlands Iris Bidco SRL Italy Fellow Subsidiary Any other transaction Expns Payable - 0.00 0.00 33.50
472 VISUfarma B.V., Netherlands Iris Bidco SRL Italy Fellow Subsidiary Loan - 0.00 0.00 24,261.50
473 VISUfarma B.V., Netherlands Iris Bidco SAS,France Fellow Subsidiary Loan - 0.00 0.00 16,318.90
474 VISUfarma B.V., Netherlands VISUfarma UK Limited, UK Fellow Subsidiary Loan - 0.00 0.00 169.30
475 VISUfarma B.V., Netherlands VISUfarma S.p.A. Italy, Italy Fellow Subsidiary Any other transaction Creditors - 0.00 0.00 1,021.50
476 VISUfarma B.V., Netherlands VISUfarma S.p.A. Italy, Italy Fellow Subsidiary Any other transaction Expns Payable - 0.00 0.00 179.60
477 VISUfarma B.V., Netherlands VISUfarma S.p.A. Italy, Italy Fellow Subsidiary Loan - 0.00 0.00 130.60
478 VISUfarma S.p.A. Italy, Italy Iris Bidco SRL Italy Fellow Subsidiary Any other transaction Creditors - 0.00 0.00 143.90
479 VISUfarma S.p.A. Italy, Italy Iris Bidco SRL Italy Fellow Subsidiary Any other transaction Debtors - 0.00 0.00 599.40
480 Lupin Pharmaceuticals, Inc., USA Lupin Management, Inc., USA Fellow Subsidiary Sale of goods or services - 77.00 0.00 0.00
481 Lupin Atlantis Holdings SA, Switzerland Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Income Receivable - 0.00 0.00 80.10
482 Lupin Atlantis Holdings SA, Switzerland Lupin Pharmaceuticals, Inc., USA Fellow Subsidiary Any other transaction Income Receivable - 0.00 0.00 548.70
483 Lupin Atlantis Holdings SA, Switzerland Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Income Receivable - 0.00 0.00 286.50
484 Lupin Inc., USA Laboratorios Grin, S.A. de C.V., Mexico Fellow Subsidiary Any other transaction Trade Payables - 0.00 23.90 42.70
485 Lupin Limited Lupin (Thailand) Limited, Thailand Wholly -Owned Subsidiary Any other transaction Application money paid towards securities - 85.00 0.00 0.00
486 Lupin Inc., USA Generic Health Pty Limited, Australia Fellow Subsidiary Any other transaction Trade Receivables - 0.00 0.00 149.90
487 Lupin Limited Nanomi B.V., Netherlands Wholly -Owned Subsidiary Any other transaction Application money paid towards securities - 0.00 0.00 39,998.10
488 Nanomi B.V., Netherlands Medquimica Industria Farmaceutica LTDA, Brazil Fellow Subsidiary Any other transaction Income Receivable - 0.00 0.00 107.80
Total value of transaction during the reporting period 13,56,407.60



Text Block

Textual Information(1) Loan given received back
Textual Information(2) Loan given received back
Textual Information(3) Loan given received back